Copyright
©The Author(s) 2024.
World J Transplant. Mar 18, 2024; 14(1): 89978
Published online Mar 18, 2024. doi: 10.5500/wjt.v14.i1.89978
Published online Mar 18, 2024. doi: 10.5500/wjt.v14.i1.89978
Table 1 Pre-transplant screening and diagnostic work-up for kidney transplant recipients
| CMV | CMV IgG serology in both donors and recipients |
| EBV | Screening by EBV serology in both donors and recipients |
| BKPyV | Not done at present |
| HSV | HSV antibodies in blood |
| VZV | Pretransplant screening for previous VZV infectio |
| Hepatitis B & C | HBV |
| HBsAg and antibody to hepatitis B core antigen (antiHBc) | |
| HCV | |
| HCV antibody test | |
| Respiratory viruses | Nasopharyngeal wash or bronchoalveolar lavage fluid (BAL) specimens (in the case of Adeno virus - stools or plasma), by conventional viral culture, PCR, or direct immunofluorescence |
Table 2 Post-transplant screening and diagnostic work-up for kidney transplant recipients
| CMV | Quantitative CMV viral load |
| Diagnosis- presence of CMV DNA in whole blood or plasma | |
| Tissue biopsy | |
| Diagnosis- presence of CMV inclusion or immunostaining | |
| CMV serology | |
| Diagnosis- presence of CMV IgG post kidney transplantation in | |
| CMV R- patients | |
| EBV | Quantitative EBV viral load |
| Tissue biopsy | |
| EBV serology | |
| BKPyV | Urine cytology |
| Quantitative BK viral load in urine | |
| Quantitative BK viral load in plasma | |
| Allograft biopsy | |
| HSV | Direct fluorescence antibody for HSV from vesicular lesions or PCR from CSF or visceral tissue samples |
| VZV | Direct fluorescence antibody for VZV from vesicular lesions or PCR from CSF or visceral tissue samples |
| Hepatitis B & C | HBV |
| HBsAg and antibody to hepatitis B core antigen (antiHBc) | |
| HCV | |
| HCV antibody test | |
| Respiratory viruses | Nasopharyngeal wash or bronchoalveolar lavage fluid (BAL) specimens, (in the case of Adeno virus - stools or plasma), by conventional viral culture, PCR, or direct immunofluorescence |
Table 3 Treatment of viral infections kidney transplant recipients
| CMV | CMV load copy no < 500 - below quantifiable level - no action |
| CMV load copy no 500-3000 - active CMV infection - repeat CMV in 1 week, consider treatment if clinically indicated | |
| CMV load copy no > 3000 - Active CMV infection - commence pre-emptive treatment | |
| Intravenous ganciclovir or oral valganciclovir | |
| EBV | Immunosuppressive drug reduction |
| Ganciclovir and valganciclovir have antiviral impact against EBV | |
| BKPyV | Immunosuppressive drug reduction |
| No specific antiviral therapy | |
| HSV | Acyclovir |
| Intravenous or oral | |
| VZV | Intravenous acyclovir, while less severe infection can be treated with oral acyclovir |
| Hepatitis B & C | Immunosuppressive drug reduction |
| Hepatitis B – Lamivudine | |
| Hepatitis C - IFN and ribavirin | |
| Respiratory viruses | Reduce immunosuppressive drugs |
| Supportive care and, in some cases, the use of antivirals |
Table 4 Prevention of viral infections kidney transplant recipients
| CMV | Valganciclovir |
| Universal prophylaxis - Dose (mg) = (7 × BSA × eGFR) once a day | |
| Preemptive therapy - Dose (mg) = ( 7 × BSA × eGFR) bd | |
| EBV | EBV viral load surveillance and preemptive therapy for EBV mismatched patients |
| BKPyV | BK viral load monitoring and early identification of BK viremia |
| HSV | Avoidance of visitors or health professionals who have HSV signs and symptoms |
| VZV | Avoidance of visitors or health professionals who have VZV signs and symptoms. Vaccination including family members |
| Hepatitis B & C | Hepatitis B vaccination and immunity verified with Hepatitis B surface antibody screening following completion of the vaccination series |
| Respiratory viruses | Avoidance of other individuals who have signs or symptoms of infection, hand hygiene, and use of droplet precautions for those suspected of having infection |
- Citation: Ranawaka R, Dayasiri K, Sandamali E, Gamage M. Management strategies for common viral infections in pediatric renal transplant recipients. World J Transplant 2024; 14(1): 89978
- URL: https://www.wjgnet.com/2220-3230/full/v14/i1/89978.htm
- DOI: https://dx.doi.org/10.5500/wjt.v14.i1.89978
